{"entity":{"id":"lidera","kind":"trial","name":"lidERA","aka":[],"tldr":"The first oral SERD to reduce recurrence after surgery, by about 30%, compared with today's hormone pills.","summary":"Presented SABCS December 2025: ~30% reduction in invasive disease-free survival events versus standard endocrine therapy, consistent across menopausal status (ASCO 2026 subgroup: 35% pre-, 26% post-menopausal). Regulatory submission planned. If approved, the first change to adjuvant endocrine backbone since aromatase inhibitors.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT04961996","url":"https://clinicaltrials.gov/study/NCT04961996"}],"tags":[],"related":[],"cancers":["breast-hr-positive","hr-positive-early-high-risk"],"sections":[],"technologies":["endocrine-therapy"],"targets":["estrogen-receptor"],"drugs":["giredestrant"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04961996","phase":"3","setting":"Adjuvant ER+/HER2- early breast cancer (medium-high risk): giredestrant vs standard endocrine therapy for 5 years","sponsor":"Roche / Genentech","participation":[{"nct":"NCT04961996","source":"https://clinicaltrials.gov/study/NCT04961996","fetchedAt":"2026-10-07T16:53:31.375Z","studySha256":"ff695e98fe28a50f6c92095dc1981e7785525fc335e70a4be52b37b1d6ae7299","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-17","leadSponsor":"Hoffmann-La Roche","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":4170,"enrolmentType":"ACTUAL","siteCount":622,"recruitingSiteCount":0,"countries":["Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Chile","China","Colombia","Costa Rica","Croatia","Czechia","Egypt","Finland","France","Georgia","Germany","Greece","Guatemala","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Kenya","Latvia","Malaysia","Mexico","Netherlands","North Macedonia","Peru","Philippines","Poland","Portugal","Romania","Serbia","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Uganda","Ukraine","United Kingdom","United States"]}],"result":"iDFS ~30% relative reduction (HR ~0.70).","started":"2021-08-27","startedType":"actual","yearReported":2025,"enrolled":4170,"enrolledBasis":"registry","outcomes":[{"endpoint":"Invasive disease-free survival","primary":true,"arms":[{"name":"Giredestrant","note":"30% reduction in iDFS events vs standard ET"},{"name":"Standard endocrine therapy"}],"hr":0.7,"source":"https://www.roche.com/media/releases/med-cor-2026-05-19"}],"replication":"Awaits CAMBRIA-1/-2 (camizestrant) and EMBER-4 (imlunestrant) adjuvant readouts."},"route":"/trials/lidera/","neighbours":{"cancer":[{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"drug":[{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"roadmap":[{"id":"hormonal-therapy-roadmap","kind":"roadmap","name":"Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test","route":"/roadmaps/hormonal-therapy-roadmap/"}]}}